Eledon's Tegoprubart Shows Lasting Promise in Kidney Transplants

IRVINE, CA – January 23, 2026 – Eledon Pharmaceuticals has unveiled promising long-term data for its investigational drug, tegoprubart, suggesting it could offer a safer and more effective alternative for kidney transplant recipients. The 24-month follow-up results from a small group of patients, presented today at the American Society of Transplant Surgeons Winter Symposium, indicate not only a strong safety profile but also a notable improvement in kidney function over time—a significant finding in a field that has seen little innovation for decades.

The data, from an eight-patient long-term extension of a Phase 1b trial, showed no instances of biopsy-proven acute rejection, graft loss, or death over the two-year period. Furthermore, patients did not develop new-onset diabetes, a common and serious side effect of current standard-of-care immunosuppressants.

Perhaps most strikingly, the study highlighted a sustained improvement in organ function. The mean estimated glomerular filtration rate (eGFR), a key measure of kidney health, increased from 67.0 mL/min/1.73 m² at the 12-month mark to 74.2 mL/min/1.73 m² at 24 months. This trend challenges the typical trajectory for transplant patients, where kidney function often declines over time due to the toxic effects of their anti-rejection medications.

A New Standard for Post-Transplant Life?

For nearly three decades, the standard of care for preventing organ rejection has been dominated by calcineurin inhibitors like tacrolimus. While effective at suppressing the immune system to prevent it from attacking the new organ, these drugs carry a heavy burden of side effects. Nephrotoxicity, or damage to the kidneys themselves, is a primary concern, creating a paradox where the medication meant to protect the graft contributes to its long-term decline.

Beyond the kidneys, patients on tacrolimus often contend with an increased risk of new-onset diabetes, tremors and other neurologic issues, and cardiovascular complications. The data from Eledon’s tegoprubart study suggests a potential escape from this trade-off. The complete absence of new-onset diabetes and the observed improvement in eGFR point toward a drug that could preserve, and even enhance, graft function without the collateral damage associated with current therapies.

"The goal in transplantation has always been a delicate balance between preventing rejection and minimizing drug toxicity," noted a transplant researcher not affiliated with the study. "An agent that can reliably prevent rejection while being actively protective of the kidney would represent a monumental step forward. It would shift the focus from merely managing decline to fostering long-term organ health and improving a patient's overall quality of life."

The Science Behind Tegoprubart

Tegoprubart’s potential lies in its highly specific mechanism of action. It is an antibody that targets the CD40 Ligand (CD40L), a critical protein that facilitates communication between immune cells. By blocking the CD40/CD40L pathway, the drug aims to modulate the immune response rather than broadly suppressing it. This pathway is a well-validated target in immunology, central to the inflammatory cascade that drives both autoimmune diseases and transplant rejection.

Eledon is building on a deep history of research into this pathway, aiming to succeed where previous efforts may have faced challenges. The goal is to create a non-lymphocyte depleting therapy that can precisely dial down the specific immune signals that lead to rejection, leaving the rest of the immune system more intact to fight infections. This targeted approach is what researchers believe may account for the favorable safety profile seen in early trials.

The Long Road from Promise to Practice

Despite the encouraging 24-month data, tegoprubart still has a long and rigorous path to navigate before it could become a clinical reality. The Phase 1b results, while compelling, are based on a very small cohort of just eight patients and lacked a randomized control group for direct comparison.

Further context comes from the company's larger Phase 2 BESTOW trial. While that study reinforced tegoprubart's favorable safety and tolerability profile compared to tacrolimus—showing dramatically lower rates of new-onset diabetes and tremor—it did not meet its primary efficacy endpoint of demonstrating a statistically significant improvement in eGFR over the standard of care at 12 months.

Nonetheless, armed with the new long-term data showing sustained eGFR improvement out to two years, Eledon plans to advance tegoprubart into a pivotal Phase 3 trial in 2026. The company’s strategy appears focused on positioning the drug as a safer alternative to tacrolimus, with the preservation of long-term kidney function as a key differentiator.

Eledon's ambitions for tegoprubart extend far beyond kidney transplantation. The company is exploring its use in other cutting-edge fields, including islet cell transplantation for type 1 diabetes, where initial results have shown promise in helping patients achieve insulin independence. It is also being investigated to prevent rejection in xenotransplantation—the transplantation of organs between different species—and as a potential treatment for the neuroinflammatory disease amyotrophic lateral sclerosis (ALS).

Challenging a Stagnant Market

Should tegoprubart succeed in late-stage trials, it would enter a substantial market ripe for disruption. The field of transplant immunosuppression has been largely stagnant, creating a significant unmet need for safer, more durable treatment options. Eledon, a clinical-stage biotech company, is positioning itself to meet that need.

The company appears financially prepared for the next steps, having recently completed a public offering that extends its cash runway through the end of 2027. This financial footing is critical for funding the expensive Phase 3 trials required for regulatory approval.

However, Eledon is not alone in its quest to innovate. Other companies, such as Hansa Biopharma with its desensitization treatment Idefirix and Biogen with its late-stage candidate felzartamab, are also developing novel therapies for transplant recipients. Tegoprubart’s potential competitive edge lies in its unique profile of combining strong safety, rejection prevention, and the potential for long-term organ function improvement. For the thousands of patients who receive a life-saving kidney transplant each year, the prospect of a treatment that protects their new organ without harming the rest of their body remains the ultimate prize.